|
|
Post by tingtongtung on Feb 24, 2019 23:22:32 GMT -5
shadydep 2/24/19, 7:04 PM @kevinmik i was going to say hopefully their upgrading but that was a decent size space Well... Every thing with MNKD *has* to be weird. Why would they want to hire another "hiring" type person? They already have a People person (something like that) - that title is as if they are one of the software startups in Bay area :-) Whatever, go MNKD! Please make us some money! |
|
|
|
Post by stockwhisperer on Feb 25, 2019 0:29:36 GMT -5
When was it last seen as reserved for them and was it just pulled? Thanks
|
|
|
|
Post by stockwhisperer on Feb 25, 2019 0:42:22 GMT -5
If all those job reqs were not out there, the ADA Booth being canceled might indicate they are leaning toward a different path. Could be they found a partner who already has a booth or like you said, maybe they just want a different booth location.
|
|
|
|
Post by babaoriley on Feb 25, 2019 1:22:05 GMT -5
Absolutely agree. It is like we are living in a different universe from the naysayers. Just want details & transparency to satisfy the Street & stop the games once & for all. MC has the power to do it - otherwise, after the call - the mystery of the black hole & consequences of what can be twisted by those w/an agenda, will carry on, "It is like we are living in a different universe from the naysayers." Whisperer, that has been true for quite a long while. And so far, I like their universe better than ours. |
|
|
|
Post by longliner on Feb 25, 2019 1:45:41 GMT -5
Absolutely agree. It is like we are living in a different universe from the naysayers. Just want details & transparency to satisfy the Street & stop the games once & for all. MC has the power to do it - otherwise, after the call - the mystery of the black hole & consequences of what can be twisted by those w/an agenda, will carry on, "It is like we are living in a different universe from the naysayers." Whisperer, that has been true for quite a long while. And so far, I like their universe better than ours. Only if you like money.............. |
|
|
|
Post by kimi on Feb 25, 2019 3:25:54 GMT -5
I do think the reason for quitting the booth is easy.
Mannkind will just change to the booth beside One drop (Booth 109,111,113)
That would make much sense!
|
|
|
|
Post by Thundersnow on Feb 25, 2019 9:44:54 GMT -5
Sorry, not sure I can "like" that... wtf? 2/24/19, 7:00 PM @kevinmik do you remember which booth we had?@kevinmik 2/24/19, 7:02 PM shadydep yes it was 2113 that is now showing vacant and available to be rented Relax people. I'm sure MNKD is negotiating a better location for their booth. They reserved a booth just to have one. As others leave they will pounce on the locations. No need to PANIC. |
|
|
|
Post by cretin11 on Feb 25, 2019 12:10:40 GMT -5
So then why did they abandon the reserved booth before pouncing on a better located one?
|
|
|
|
Post by #NoMoreNeedles on Feb 25, 2019 13:01:01 GMT -5
Mike says that the booth was in a horrible location, that's why they pulled the space. They are supporting ADA in other ways. Majority of attendees are not from the USA and therefore not their primary target audience.
|
|
|
|
Post by ltta on Mar 10, 2019 10:34:31 GMT -5
3/7/2019 Title Director/Executive Director, Regulatory Affairs & Safety City Westlake Village State CA rew12.ultipro.com/MAN1011/JobBoard/JobDetails.aspx?__ID=*7920110FCE12D19BThe Director/Executive Director, Regulatory Affairs and Safety will be responsible for developing and leading regulatory strategies and activities for the organization, including clinical and commercial regulatory submissions on a global basis. This includes ensuring that all corporate regulatory goals are clearly defined, met and are in compliance with all current industry standards globally. This role will provide significant input on regulatory affairs processes, procedures, and tools to facilitate effective execution by the regulatory function across the organization. This individual must be highly skilled and provide expertise in both clinical and nonclinical regulatory strategy. In addition, this position also serves as the Global Safety Officer with responsibility for managing and overseeing MannKind’s drug safety and pharmacovigilance process. This includes managing compliance with standard operating procedures; regulatory safety and pharmacovigilance in compliance with national and international regulations, such as the Food and Drug Administration (FDA) and EMEA; and global, regional and country regulations for the reporting of adverse events to regulatory agencies. This role will have oversight of an internal Regulatory & Safety team, be a key member of the R&D leadership team, and requires a candidate with a deep knowledge and understanding of the global regulatory environment and a passion for patient care. |
|
|
|
Post by mnkdfann on Mar 10, 2019 10:48:55 GMT -5
From the second post above, dated Feb 25, 2019: "Majority of attendees are not from the USA and therefore not their primary target audience." Next post, quoting March 7, 2019 job advert: Wanted: Global Safety Officer with "deep knowledge and understanding of the global regulatory environment."  |
|
|
|
Post by akemp3000 on Mar 10, 2019 11:23:07 GMT -5
Mike Castagna knows what the company needs especially considering his two prior positions at Amgen: 1) Vice President Global Life Cycle Managemement and 2) Global Commercial Lead for Amgen's Biosimilar Unit. In his brief tenure as CEO of Mannkind, he's done a good job completely overhauling the business plan and balancing the company's efforts for both Afrezza and the pipeline development. This new position indicates he also sees an immediate future requiring international support and development. I hope this is foreshadowing more good news.
|
|
|
|
Post by barnstormer on Mar 10, 2019 11:26:21 GMT -5
From the second post above, dated Feb 25, 2019: "Majority of attendees are not from the USA and therefore not their primary target audience." Next post, quoting March 7, 2019 job advert: Wanted: Global Safety Officer with "deep knowledge and understanding of the global regulatory environment." There are two troubling things. Mike told me when ADA was in San Diego they weren't going because the majority of attendees are not from the US. I can tell you that a large number of the attendees were there from the US including endos, nurse practioners and others that can help move Afrezza forward. Otherwise why did we have to wait for the STAT last year until ADA? The collaborators knew there was a strong US attendance to deliver the study too in a live setting. Secondly the hires they are making clearly reflect that were are not nearing a partnership with a big pharma company that already has regulatory and global regulatory talent in. Why duplicate? Mike did say they would look into other ways to participate in ADA. I guess we will see photos of some presense there. I would suggest that many of the global regulators will have delegates at ADA, so why not impress them ahead of a filing for approval for Afrezza? Troubling. |
|
|
|
Post by sportsrancho on Mar 10, 2019 11:40:46 GMT -5
Good points Gary.
|
|
|
|
Post by akemp3000 on Mar 10, 2019 13:07:06 GMT -5
Calling it troubling could be fair but that's pure speculation and possibly misleading...just as it would be pure speculation and possibly misleading to believe that there could be positive things going on behind the scenes that are not being disclosed that led to the decision. Since we don't know, there's no reason to value one speculation over the other. Guessing is certainly fair.
|
|
